. Author manuscript; available in PMC: 2023 Aug 1.

Published in final edited form as: Histopathology. 2022 Jul 11;81(2):246–254. doi: 10.1111/his.14707

Table 1.

Breakdown of primary vs. metastatic cases for tumors with neuroendocrine differentiation in the setting of prostate cancer

Category	Primary	Metastatic
Pure small cell carcinoma / HGNEC	3/23	20/23
Combined adenocarcinoma + small cell carcinoma / HGNEC	9/10	1/10
PCa with diffuse neuroendocrine differentiation	0/15	15/15
PCa with patchy neuroendocrine differentiation	5/11	6/11
PCa with isolated neuroendocrine marker positive cells	4/9	5/9
PCa with prominent neuroendocrine granules (‘Paneth cell-like’)	11/11	0/11
Total	32	47

HGNEC: high-grade neuroendocrine carcinoma; PCa: prostate cancer